Skip to main content

Table 3 Estimates of number of AMIs, strokes, and CVD deaths that could be prevented (2016–2030)

From: Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China

  AMIs averted (2016–2030) Strokes averted (2016–2030) CVD deaths averted (2016–2030)
Lipid management    
 Total population 9,718,958 7,822,617 3,359,026
 At least one other CVD risk factor 8,861,135 6,955,115 3,034,802
  > 55 years 7,847,580 6,798,342 3,039,769
  > 65 years 5,330,256 5,124,158 2,497,361
Blood pressure management    
 Total population 12,690,319 24,090,474 7,322,172
 At least one other CVD risk factor 11,705,084 21,439,156 6,570,986
  > 55 years 10,850,141 21,062,444 6,822,105
  > 65 years 7,150,355 14,382,099 5,453,613
Lipid and blood pressure management    
 Total population 19,621,753 29,640,863 9,713,259
 At least one other CVD risk factor 18,020,822 26,371,553 8,730,106
  > 55 years 16,431,006 25,878,475 8,982,422
  > 65 years 10,932,970 18,007,273 7,226,067
  1. The three targeted approaches to lipid and blood pressure management include (i) treating all those with hyperlipidemia with a measure of LDL-C >130 mg/dL and/or hypertensives with SBP > 140 mmHg who had at least one other CVD risk factor; (ii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP >140 mmHg) and ages 55 years or older; and (iii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP >140 mmHg) and ages 65 years or older. Data are based on authors’ calculations
  2. AMI acute myocardial infarction, CVD cardiovascular disease